Most synthetic peptides are built one amino acid at a time on a resin bead, a method called solid-phase peptide synthesis. This guide walks through each step, explains why a fraction of a percent of yield per step decides the quality of the result, shows where impurities come from, and follows the peptide from crude product to finished vial.
Key takeaways
- Most peptides today are manufactured by solid-phase peptide synthesis (SPPS): the chain is grown one amino acid at a time while anchored to an insoluble resin.
- Anchoring the chain lets every step be cleaned up by filtering and washing, which replaced a separate purification after each reaction.
- Yield per step is everything. At 90% per step a 100-step synthesis returns about 0.003% of product; at 99.5% it returns about 61%.
- The steps that fall short of 100% are where impurities come from: missing amino acids, extra amino acids and mirror-image residues.
- Synthesis produces a crude mixture. Purification by HPLC, identity testing and freeze-drying turn it into a finished lot, and the certificate of analysis reports the result.
ImportantResearch use only. This guide explains how synthetic peptides are manufactured and tested as laboratory research materials. It does not describe human or animal use. Codex Research compounds are not approved by the FDA and are sold for in-vitro laboratory research only.
Quick answer
Most peptides today are made by solid-phase peptide synthesis (SPPS) [6]. The first amino acid is attached to an insoluble resin bead, and the others are added one at a time in a repeating cycle: remove a protecting group, wash, couple the next amino acid, wash again [3]. When the sequence is complete, the peptide is cut from the resin, purified by HPLC and freeze-dried.
The method works because the growing chain never leaves the bead. Leftover reagents are simply washed away, so each step can be pushed close to 100% completion [1][3]. The small shortfall at each step is where a synthetic peptide’s impurities come from [6].
Terms you will see
| Term | Plain meaning |
|---|---|
| SPPS | Solid-phase peptide synthesis: building a peptide while it is attached to a solid support |
| Resin | The insoluble polymer beads the chain is anchored to |
| Protecting group | A chemical cap that blocks a reactive position until it is needed |
| Deprotection | Removing the temporary cap from the end of the chain |
| Coupling | Joining the next amino acid to the chain |
| Cleavage | Releasing the finished chain from the resin |
| Crude peptide | The unpurified product that comes off the resin |
| Deletion sequence | An impurity that is missing one amino acid |
| C-terminus, N-terminus | The two ends of a peptide chain: the carboxyl end and the amino end |
Are peptides natural or synthetic?
Both. A peptide is a short chain of amino acids, and the same chain can be made by a cell or by a chemist.
In living things, peptides are built on ribosomes, which join amino acids in the order set by a genetic template. Many peptide hormones start out as part of a longer protein and are trimmed to size by enzymes.
In the laboratory, the same sequence is assembled chemically from individual amino acids. Every research peptide sold in a vial is made this way. A synthetic peptide with the correct sequence is the same molecule as its natural counterpart. What differs between sources is the set of minor by-products that travel with it, which is why testing matters more than origin.
Three ways peptides are produced
| Route | How it works | Typical use |
|---|---|---|
| Solid-phase chemical synthesis | The chain is built stepwise on a resin bead | Most synthetic peptides, from research quantities to commercial production [4][6] |
| Solution-phase chemical synthesis | The same chemistry carried out with everything dissolved | Still valuable for large-scale manufacturing and special cases [3] |
| Recombinant (rDNA) production | Cells are engineered to make the chain, which is then extracted | Some approved peptide drugs [13] |
The routes are not rivals so much as tools for different jobs. FDA guidance issued in 2021 deals with exactly this overlap: it covers synthetic versions of five approved peptide drugs that were originally made by recombinant DNA technology [13].
Before 1963: why peptides were so hard to make
The basic chemistry for joining amino acids was worked out by Emil Fischer, who won the Nobel Prize in Chemistry in 1902 [1]. Joining two amino acids was manageable. Joining many was not.
The Nobel committee later described the method as simple in theory but difficult in practice. After every reaction, the product had to be separated from by-products and unreacted starting material, and some product was lost each time [1]. Its arithmetic makes the problem plain: at a 90% yield per step, a synthesis of 100 steps returns about 0.003% of the theoretical product [1].
Chemists still managed remarkable results. Vincent du Vigneaud, the 1955 Nobel laureate in chemistry, synthesized the peptide hormone oxytocin, which the committee called a very great step forward [1]. But each new peptide was a major project.
Merrifield’s idea: build it on a bead
R. Bruce Merrifield of Rockefeller University changed the procedure rather than the chemistry. He attached the first amino acid, through its carboxyl group, to a solid polymer [1]. The chain then grew on that support, and after each reaction the by-products and leftover reagents were removed by filtration and washing instead of a full purification [1].
He first reported the method in 1962 and described it in detail in a 1963 paper [2]. The effect on yield was dramatic. With each step running at 99.5% or better, the 100-step example that returned 0.003% now returned about 61% [1].
Two more consequences followed:
- Automation. A procedure made of repeated additions and washes suits a machine, and automatic peptide synthesizers became commercially available [1].
- Scale of ambition. In 1969 Merrifield and Bernd Gutte used an automated synthesizer to make ribonuclease A, an enzyme of 124 amino acids [2].
Merrifield received the 1984 Nobel Prize in Chemistry "for his development of methodology for chemical synthesis on a solid matrix" [1]. The same principle was later applied to the synthesis of DNA fragments [1].
How solid-phase peptide synthesis works, step by step
A peptide is assembled from its C-terminus to its N-terminus, the reverse of the order in which the sequence is usually written [3].
- Anchor the first amino acid. The C-terminal amino acid is attached to an insoluble resin [3].
- Deprotect. The incoming amino acids carry a temporary protecting group on their amino end. It is removed from the last residue on the chain to expose a reactive site.
- Wash. Solvent is passed through the resin to carry away what was removed.
- Couple. The next protected amino acid is added with a coupling reagent, in excess, so the reaction is driven toward completion [3].
- Wash. Excess amino acid and reagent are filtered off. Nothing is lost from the chain, because the chain is fixed to the bead [3].
- Repeat steps 2 to 5 for every amino acid in the sequence.
- Cleave. When the chain is complete, the crude peptide is released from the support [3], and the protecting groups on its side chains are removed.
What comes off the resin is not a finished product. It is a crude peptide: mostly the target sequence, mixed with every by-product of the cycles before it.
Protecting groups: Boc and Fmoc
An amino acid has two reactive ends, and many have a reactive side chain as well. Left unprotected, they would join in the wrong places or to each other. Protecting groups block every position except the one that is meant to react.
Two schemes have dominated.
| Boc chemistry | Fmoc chemistry | |
|---|---|---|
| Era | The original solid-phase approach | Adopted for solid-phase work in the late 1970s [3] |
| Temporary group removed with | Acid, in every cycle | Mild base |
| Final release from the resin | Hydrogen fluoride [4] | Acid, with side-chain groups designed to come off at the same time [4] |
| Automation | Harder: corrosive acid in every cycle | Easier: no corrosive acid in the cycles [4] |
| Monitoring | Less direct | Each removed Fmoc group absorbs UV light, giving a built-in check on the synthesis [4] |
Fmoc chemistry is now the method of choice, and the majority of synthetic peptides are prepared this way [4]. Because the two kinds of protecting group are removed under different conditions, the scheme is described as orthogonal, which gives chemists wide freedom in what they can build [5]. Its scale has had a practical consequence: high-quality Fmoc building blocks are available at low cost because therapeutic peptides are produced by this method in multi-ton quantities [4]. Most automated synthesis uses the Fmoc scheme, and instruments have progressed from conventional designs to microwave-assisted ones [11].
Why a fraction of a percent matters
The Nobel committee’s example can be extended to chain lengths closer to a research peptide. The table shows the share of chains that come through every step intact.
| Yield per step | 10 steps | 20 steps | 30 steps | 40 steps |
|---|---|---|---|---|
| 90% | 34.9% | 12.2% | 4.2% | 1.5% |
| 98% | 81.7% | 66.8% | 54.5% | 44.6% |
| 99% | 90.4% | 81.8% | 74.0% | 66.9% |
| 99.5% | 95.1% | 90.5% | 86.0% | 81.8% |
These figures are plain compounding (yield per step raised to the number of steps), not measured data. They show two things. Longer peptides are harder to make cleanly, and the gap between 99% and 99.5% per step, which sounds trivial, is the gap between two-thirds and four-fifths of the chains being correct at 40 steps.
Where impurities come from
Every chain that fails a step becomes an impurity, and because it differs from the target by very little, it is hard to remove. A review of peptide-related impurities groups the synthesis-related ones by cause [6]:
| Impurity | Cause |
|---|---|
| Deletion sequences (one amino acid missing) | Incomplete removal of the Fmoc group, so the next amino acid cannot attach |
| Insertion sequences (one amino acid repeated) | Excess amino acid reagent |
| Diastereomers (a mirror-image residue) | Racemization during the chemistry |
| Protection adducts | Side-chain protecting groups not fully removed |
| Side-chain modifications | Unprotected side chains reacting with synthesis reagents; oxidation |
The raw materials matter too. Impurities in the amino acid building blocks are carried into the growing chain, and free amino acid in a building block can lead to multiple copies of the same residue being incorporated [4]. Some sequences bring their own problems. The most serious side reaction in Fmoc chemistry, aspartimide formation, occurs when a chain containing aspartic acid is exposed to strong base, which makes long peptides and those with several aspartic acid residues harder to make [4].
The same review warns that these impurities can influence early functional studies and lead to erroneous conclusions [6]. Our guide to peptide purity grades covers what a 95%, 98% or 99% figure means in terms of how much of this material remains.
From crude peptide to finished lot
Synthesis is the first half of manufacturing. The second half turns a crude mixture into a characterized lot.
- Purification. HPLC has been the workhorse for isolating and purifying peptides for decades, and preparative reversed-phase chromatography is a routine way to separate a target peptide from its close relatives [9].
- Analysis. The purified material is tested: analytical HPLC for purity and mass spectrometry for identity. Our guide to HPLC and mass spectrometry explains what each one proves.
- Freeze-drying. The peptide is filled into vials as a solution and lyophilized, a process in which the product is frozen and its water removed under vacuum [12]. Our guide to lyophilized peptides covers that step.
- Release testing. The finished lot is tested again, and the results are recorded on its certificate of analysis.
The choices made in purification leave a mark on the product. The acids used in chromatography and in cleavage stay with the peptide as counter-ions, which is part of the reason a vial’s powder weight is more than its peptide weight.
How long a chain can chemistry build?
Stepwise synthesis has no fixed ceiling, but the compounding shown above sets a practical one. The 124-residue ribonuclease A synthesis of 1969 proved that medium-sized proteins were within reach [2], and there have been considerable advances since in the length of peptides that can be made [4].
For larger targets, chemists stopped trying to make the whole chain in one run. Native chemical ligation, introduced in 1994, joins two unprotected peptide segments through a reaction that leaves a normal peptide bond at the junction, which allows the direct synthesis of proteins of moderate size [10].
Scale and the cost of making peptides
Chemical synthesis now supplies an industry. More than 80 peptide drugs have reached the market since insulin was introduced about a century ago [8]. A 2019 perspective counted more than 50 on the market at that time, about 170 in clinical trials and more than 200 in preclinical development [7].
The same paper is frank about the method’s weakness: peptide synthesis still relies on large amounts of highly hazardous reagents and solvents. In 2016 the American Chemical Society’s Green Chemistry Institute Pharmaceutical Roundtable named greener processes for peptide manufacturing a critical unmet need [7].
This is the background to price differences between suppliers. Solvent, building blocks, purification losses and testing all cost money, and each can be cut back in ways that do not show on a label.
Common misconceptions
- "Synthetic means artificial or inferior." A synthetic peptide with the right sequence is the same molecule as the natural one. Quality depends on what else is in the vial.
- "Synthesis produces a pure peptide." It produces a crude mixture. Purity is the result of purification and is measured afterwards [9].
- "All suppliers make peptides the same way." The chemistry is shared, but resin, building-block quality, cycle conditions and how hard the product is purified all vary [4].
- "A longer peptide is just more of the same work." Each added residue compounds the losses, and some sequences are harder than their length suggests [4].
- "Lab-made peptides are a recent invention." The solid-phase method dates from the early 1960s [2].
What the synthesis route does not tell you
Knowing how a peptide was made describes a manufacturing process. It does not establish the identity, purity or content of any particular lot, which only testing can show. It does not describe how a compound behaves in any organism or establish safety or effectiveness for any use. Research materials are not held to the standards that apply to approved drugs, and research compounds are not approved by the FDA for human or veterinary use.
How Codex Research handles manufacturing and testing
Codex Research peptides are made in the United States and lab tested by lot. Published Codex Research certificates judge purity against a specification of 98.0% or higher by reversed-phase HPLC, and full reports also confirm identity by LC-MS. Each product page shows the results for the lot currently shipping.
Every vial is supplied lyophilized and ships the same day when ordered before 3 PM ET on a weekday. To check a certificate against the lab that issued it, read our guide to spotting a fake COA, or see why US manufacturing matters for how origin affects transit and traceability. For the certificate behind any lot, contact info@codexresearch.shop.
Frequently asked questions
How are peptides made?
How are peptides made in a lab?
Are peptides synthetic or natural?
How are peptides made in the body?
What is solid-phase peptide synthesis?
Who invented solid-phase peptide synthesis?
What are the steps of solid-phase peptide synthesis?
What is Fmoc in peptide synthesis?
What is the difference between Fmoc and Boc synthesis?
Why are protecting groups needed?
How long a peptide can be made by chemical synthesis?
Where do impurities in synthetic peptides come from?
How are peptides purified after synthesis?
Is a synthetic peptide the same as the natural one?
Where are Codex Research peptides made?
References
- The Royal Swedish Academy of Sciences. Press release: The Nobel Prize in Chemistry 1984. NobelPrize.org.
- American Peptide Society. Bruce Merrifield, 1979 Merrifield Award recipient.
- Stawikowski M, Fields GB. Introduction to peptide synthesis. Curr Protoc Protein Sci. 2012;Chapter 18:Unit 18.1.
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27.
- Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 1990;35(3):161-214.
- D’Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30.
- Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability challenges in peptide synthesis and purification: from R&D to production. J Org Chem. 2019;84(8):4615-4628.
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325.
- Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods Mol Biol. 2007;386:3-55.
- Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native chemical ligation. Science. 1994;266(5186):776-779.
- Mäde V, Els-Heindl S, Beck-Sickinger AG. Automated solid-phase peptide synthesis to obtain therapeutic peptides. Beilstein J Org Chem. 2014;10:1197-1212.
- U.S. FDA. Guide to Inspections of Lyophilization of Parenterals (7/93). Inspection Guides.
- U.S. FDA. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. Guidance for Industry, May 2021.






































